MSc Biotherapeutics and Business

1 Year On Campus Masters Program

University College Dublin

Program Overview

The MSc Biotherapeutics & Business at University College Dublin is a one‑year master’s program that combines cutting‑edge scientific training in biotherapeutics with a comprehensive business education. It suits science graduates who want to understand the full pipeline of drug discovery and development while gaining the commercial and leadership skills to thrive in the global biopharma industry.

Curriculum Structure

Autumn Trimester
Students begin with a strong scientific foundation in modules such as Biotherapeutic Pipeline I and The Business of Biotechnology and Science. These courses introduce the discovery of biomolecular drug candidates, antibody engineering, and commercialization challenges. Alongside, Marketing Management and Professional Career Development sharpen communication and leadership skills.

Spring Trimester
The second stage deepens scientific expertise with Biotherapeutic Pipeline II and Systems Biology in Drug Development, expanding knowledge of biochemical and biophysical characterization and systems‑level approaches to drug discovery. In parallel, business modules such as Business Strategy, Organisational Behaviour, and Corporate Finance equip students with the tools to evaluate investments, manage teams, and design growth strategies.

Summer Trimester
The program culminates in applied projects. Through Feasibility and Business Plan and the Biotherapeutics Case Study, students integrate science and business by developing commercialization strategies for new drug entities. This stage emphasizes independent thinking, problem‑solving, and applied research, ensuring graduates can bridge the gap between laboratory innovation and market success.

Focus Areas

Biotherapeutic drug discovery, antibody engineering, bioprocessing, commercialization strategy, corporate finance, marketing management, regulatory affairs.

Learning Outcomes

Graduates will:

Demonstrate comprehensive understanding of biotherapeutics development and business principles.
Apply knowledge to overcome commercialization challenges in biotech.
Conduct applied valuation studies of new drug entities.
Collaborate with scientists and entrepreneurs to develop innovative solutions.
Communicate research effectively and manage projects in professional settings.

Professional Alignment (Accreditation)

This NFQ Level 9 Master’s program has been developed in consultation with employers and integrates a business development plan, ensuring graduates are recognized and valued by leading biopharma companies worldwide.

Reputation (Employability Rankings)

UCD is ranked among the top 1% of universities worldwide and consistently performs strongly in QS Graduate Employability Rankings. Employers such as Abbott, Amgen, Baxter Healthcare, Eli Lilly, GSK, Janssen, MSD, and Johnson & Johnson actively recruit graduates from this program.

Experiential Learning (Research, Projects, Internships etc.)

One of the most exciting aspects of UCD’s MSc Biotherapeutics & Business is how it blends classroom learning with real-world practice. Students gain hands-on experience in mammalian cell culture and bioprocess laboratories, while also working on business case studies and commercialization projects that mirror the challenges faced by global biopharma companies. Delivered jointly by the UCD School of Biomolecular and Biomedical Science and the UCD Michael Smurfit Graduate Business School, the program ensures you develop both scientific expertise and business leadership skills in authentic settings.

Here’s how experiential learning is built into the program:

Laboratory Facilities: Students train in mammalian cell culture and bioprocess laboratories, learning practical techniques in antibody engineering, biochemical characterization, and systems biology.
Group Projects & Case Studies: The Biotherapeutics Case Study module requires teamwork to evaluate real drug development pipelines, integrating scientific and business perspectives.
Business Plan Development: Through the Feasibility and Business Plan module, students design commercialization strategies for new drug entities, applying financial modeling and market analysis taught at Smurfit Business School.
Digital Tools: Systems biology software and bioprocess modeling tools are used to simulate drug development processes, enhancing the ability to translate lab data into business insights.
Industry Exposure: Guest lectures and collaborations with Ireland’s biopharma sector, including Pfizer, MSD, ICON plc, and AstraZeneca, provide direct insight into how leading companies operate.
Library & Research Resources: Students benefit from UCD’s extensive scientific databases and Smurfit’s business library, supporting both technical and commercial research.
Institute Connections: The program leverages UCD’s partnerships with institutes such as the National Institute for Bioprocessing Research and Training (NIBRT), offering exposure to facilities that replicate real biopharmaceutical manufacturing environments.

Progression & Future Opportunities

Graduates of UCD’s MSc Biotherapeutics & Business are uniquely prepared to take on leadership roles in the biopharma sector. With advanced training in drug discovery and commercialization, alumni typically progress into careers such as Regulatory Affairs Specialist, Bioprocess Scientist, Business Development Manager, and Clinical Research Associate. The program’s dual focus on science and business ensures graduates are highly employable across Ireland’s thriving life sciences industry and internationally:

Career Services: Students benefit from UCD’s Career Development Centre and the Smurfit Graduate Business School Career Service, which provide tailored workshops, employer networking events, and one‑to‑one coaching to secure interviews and placements.
Employment Outcomes: UCD highlights strong graduate employability, with alumni securing positions in leading companies such as Abbott, Amgen, Baxter Healthcare, Eli Lilly, GSK, Janssen, MSD, and Johnson & Johnson.
Industry Partnerships: The program leverages UCD’s close ties with Ireland’s biopharma ecosystem, including collaborations with Pfizer, MSD, ICON plc, AstraZeneca, and NIBRT (National Institute for Bioprocessing Research and Training), ensuring students gain exposure to real industry challenges.
Accreditation Value: As a Level 9 NFQ Master’s qualification, the degree holds long‑term recognition both in Ireland and internationally, supporting career mobility across regulated biotech and pharmaceutical industries.
Graduate Outcomes: Alumni testimonials emphasize progression into regulatory affairs, business strategy roles, and research positions, demonstrating the program’s ability to open diverse career pathways.

Further Academic Progression:
After completing the MSc Biotherapeutics & Business, students may continue into PhD research programs within UCD’s School of Biomolecular and Biomedical Science or pursue advanced doctoral studies in bioprocessing, regulatory science, or biotechnology commercialization. This pathway allows graduates to deepen their expertise and prepare for leadership roles in academia, research, or industry innovation.